Viking Therapeutics Inc (NASDAQ:VKTX) – Research analysts at Svb Leerink raised their Q1 2019 earnings per share estimates for shares of Viking Therapeutics in a research note issued to investors on Monday, March 11th. Svb Leerink analyst P. Sarraf now anticipates that the biotechnology company will post earnings per share of ($0.07) for the quarter, up from their previous estimate of ($0.08). Svb Leerink has a “Mkt Perform” rating on the stock. Svb Leerink also issued estimates for Viking Therapeutics’ Q2 2019 earnings at ($0.07) EPS, Q3 2019 earnings at ($0.13) EPS, Q4 2019 earnings at ($0.17) EPS, FY2019 earnings at ($0.57) EPS, Q1 2020 earnings at ($0.17) EPS, Q2 2020 earnings at ($0.17) EPS, Q3 2020 earnings at ($0.18) EPS, Q4 2020 earnings at ($0.19) EPS, FY2020 earnings at ($0.72) EPS, FY2021 earnings at ($0.86) EPS, FY2022 earnings at ($1.12) EPS and FY2023 earnings at ($1.87) EPS.
VKTX has been the subject of a number of other reports. Maxim Group decreased their price objective on Viking Therapeutics from $28.00 to $20.00 and set a “buy” rating for the company in a report on Thursday. B. Riley assumed coverage on Viking Therapeutics in a report on Tuesday, December 11th. They set a “buy” rating and a $16.00 price objective for the company. Leerink Swann assumed coverage on Viking Therapeutics in a report on Friday, February 22nd. They set a “market perform” rating and a $10.00 price objective for the company. Raymond James upgraded Viking Therapeutics from an “outperform” rating to a “strong-buy” rating and set a $43.00 price objective for the company in a report on Monday, November 19th. They noted that the move was a valuation call. Finally, William Blair reissued an “outperform” rating on shares of Viking Therapeutics in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $22.88.
Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Wednesday, March 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.03.
A number of hedge funds and other institutional investors have recently modified their holdings of VKTX. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Viking Therapeutics during the fourth quarter valued at approximately $30,000. Lindbrook Capital LLC acquired a new position in Viking Therapeutics during the fourth quarter valued at approximately $36,000. Great West Life Assurance Co. Can acquired a new position in Viking Therapeutics during the fourth quarter valued at approximately $53,000. Meeder Asset Management Inc. boosted its position in Viking Therapeutics by 63.5% during the fourth quarter. Meeder Asset Management Inc. now owns 7,309 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 2,839 shares during the last quarter. Finally, Nisa Investment Advisors LLC acquired a new position in Viking Therapeutics during the fourth quarter valued at approximately $60,000. 65.69% of the stock is owned by hedge funds and other institutional investors.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
See Also: Hedge Funds – Risk or Reward?
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.